|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 全胃切除调节型双通道间置空肠消化道重建显示文摘目的介绍一种新的全胃切除消化道重建术。方法选取我院2004年6月至2006年3月期间行全胃切除病例38例。在行消化道重建时,对功能性空肠间置代胃(FJI)术作如下改良:将输出袢适度丝线结扎改为部分缩窄缝合2~3针,适当缩短输入袢肠管至20~25cm,Braun吻合口距Treitz韧带10cm,以食管空肠及Braun吻合口无张力为度。结果全组病例无围手术期死亡、吻合口漏及倾倒综合征发生。Roux-en-Y滞留综合征2例;返流性食管炎1例;Visick分级:35例Ⅰ级,3例Ⅱ级。血清营养学指标:仅2例血红蛋白低于正常。术后6个月,36例进食量和体重恢复术前水平,仅2例体重下降。造影钡剂主要进入十二指肠通道,少量通过部分缩窄通道。结论对FJI重建术的改良,不仅保留了原法的全部优点,而且可进一步降低并发症,改善患者生活质量,但需进行进一步的前瞻性对比研究。 | 肖仕明 姜淮芜 陈进 肖平 郭海燕 孙燕 | 2008 | 中国普外基础与临床杂志2008，15，1： | 31 |
| 2 | Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer:One institution's experience显示文摘AIM:To investigate the predictive clinical value of in vitro 3-(4,5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) assay for directing chemosensitivity in patients with gastric cancer. METHODS:Results of a total of 353 consecutive patients with gastric cancer treated with MTT-directed chemotherapy or physician’s empirical chemotherapy from July 1997 to April 2003 were reviewed and analyzed retrospectively. RESULTS:The overall 5-year survival rate of MTT- sensitive group (MSG) and control group (CG) was 47.5% and 45.1%, respectively. The results of subgroup analysis with Cox proportional-hazards model were favorable for the MSG-sensitive group. However, no statistically significant difference in survival rate was observed between the two groups. CONCLUSION:Individualized chemotherapy based on in vitro MTT assay is beneficial, but needs to be confirmed by further randomized controlled trials. | Bin Wu Jin-Shui Zhu Yi Zhang Wei-Ming Shen Qiang Zhang | 2008 | World Journal of Gastroenterology2008，14，19： | 22 |
| 3 | 胃癌肝转移的化疗和靶向治疗显示文摘胃癌是中国人常见的恶性肿瘤.其生物学行为比较复杂。肝脏是胃癌患者转移的好发部位。与结直肠癌不同,胃癌肝转移常同时伴有远处淋巴转移、其他脏器转移和腹膜种植转移。针对胃癌仅伴有肝转移的病例,经过术前治疗可以获得手术切除病灶的机会.积极手术还是继续保守治疗争议较大。小样本的临床观察提示。手术可能使患者生存期延长。何种围手术期治疗方案可使更多的患者获得手术机会,目前尚无一致的认识。紫杉类、铂类和氟尿嘧啶类化疗药物以及抗人表皮生长因子受体-2的靶向治疗在晚期胃癌患者的治疗中均显示出较高的治疗反应率。这些方案在胃癌肝转移转化性治疗中的作用值得进一步分析和评价。 | 苏丹 白莉 | 2014 | 中华胃肠外科杂志2014，17，2： | 16 |
| 4 | 多烯紫杉醇联合顺铂腹腔化疗治疗进展期胃癌45例显示文摘目的:探讨多烯紫杉醇及顺铂联合腹腔化疗治疗进展期胃癌的疗效.方法:对45例进展期胃癌患者进行多烯紫杉醇及顺铂联合腹腔化疗,比较腹腔化疗前后两组肿瘤体积大小、血常规、肝肾功的变化,观察腹腔化疗术后的不良反应,并对所有患者进行随访观察其生存时间.结果:腹腔化疗后胃癌体积明显缩小(72.4±22.4cm3vs7.23±2.4cm3,t=2.946,P<0.01),患者中位生存期为14.0±1.4mo,对癌性腹水近期有效率为59%.腹腔化疗对患者血常规、肝肾功能中部分指标有一定影响,主要不良反应为脱发、口腔炎、便秘及血尿.结论:多烯紫杉醇及顺铂联合腹腔化疗治疗胃癌疗效好,能明显缩小肿瘤体积,延长患者生存期,减少癌性腹水,且操作方便,不良反应少. | 郭花 朱金水 张强 达炜 孙群 陈尼维 | 2008 | 世界华人消化杂志2008，16，20： | 12 |
| 5 | 老年胃癌术后患者118例的预后分析显示文摘目的:研究老年胃癌患者的临床因素以及术后化疗对预后产生的影响.方法:对1997-01/2006-01我院收治的老年胃癌术后患者118例进行回顾性分析,采用Kaplan-Meier和Cox回归分析评价性别、临床分期、组织学分化、浸润深度、淋巴结转移、远处转移、脉管癌栓、手术切除淋巴结数量、术后肿瘤残留及术后化疗等因素对预后的影响.结果:单因素分析显示临床分期、浸润深度、淋巴结转移、远处转移、术后化疗和肿瘤残留情况与预后明显相关(P<0.05).多因素分析证实,术后化疗、肿瘤残留情况及临床分期为预后的独立因素(P=0.000,P=0.000和P=0.002).结论:术后化疗、肿瘤残留情况及临床分期是老年胃癌术后患者预后的独立危险因素,Ⅲ期及Ⅳ期老年患者接受术后化疗具有明显的生存优势,但是,术后化疗并未改善Ⅰ期及Ⅱ期老年患者的生存期. | 张煜 马力文 梁莉 | 2007 | 世界华人消化杂志2007，15，31： | 10 |
| 6 | Correlation between the survival rate of the patients with synchronous hepatic metastases from gastric carcinoma after surgical resection and patient's index显示文摘许多研究报导了的背景肝的切除术为的利益独居并且从胃的 cancer.However 的 metachronous 转移,为从胃的癌的同步肝的转移的指示和外科的结果一直不清楚地是 defined.This 学习被执行估计主要胃的癌症和同步肝的转移的同时的联合切除术的好处和限制,以及识别影响在1月2日之间的 survival.Methods | YANG Xin-wei LI Zhe LIU Kai FU Xiao-hui YANG Jia-he WU Meng-chao | 2012 | Chinese Medical Journal2012，，5： | 8 |
| 7 | 曲妥珠单抗在Her-2高表达胃癌治疗中的研究近况显示文摘目的:了解曲妥珠单抗(赫赛汀)在人表皮生长因子受体2(Her-2)高表达胃癌治疗中的研究近况。方法:对近年来曲妥珠单抗(赫赛汀)在Her-2高表达胃癌治疗中研究情况的文献资料进行分析,并对Her-2相关的检测方法进行探讨。结果:曲妥珠单抗(赫赛汀)在体内外能够抑制Her-2高表达胃癌细胞的生长,Ⅱ、Ⅲ期临床试验结果显示它能明显提高Her-2高表达胃癌患者的疗效和生活质量,显著延长生存时间。结论:曲妥珠单抗(赫赛汀)有望成为一种新型的治疗胃癌的生物靶向药物。 | 章娟 吴洪斌 翟青 | 2010 | 中国医院用药评价与分析2010，10，5： | 7 |
| 8 | Synergistic anticancer properties of docosahexaenoic acid and 5-fluorouracil through interference with energy metabolism and cell cycle arrest in human gastric cancer cell line AGS cells显示文摘AIM: To explore the synergistic effect of docosahexaenoic acid(DHA)/5-fluorouracil(5-FU) on the human gastric cancer cell line AGS and examine the underlying mechanism.METHODS: AGS cells were cultured and treated with a series of concentrations of DHA and 5-FU alone or in combination for 24 and 48 h. To investigate the synergistic effect of DHA and 5-FU on AGS cells, the inhibition of cell proliferation was determined by MTT assay and cell morphology. Flow cytometric analysis was also used to assess cell cycle distribution, and the expression of mitochondrial electron transfer chain complexes(METCs)?Ⅰ, Ⅱ and Ⅴ in AGS cells was further determined by Western blot analysis. RESULTS: DHA and 5-FU alone or in combination could markedly suppress the proliferation of AGS cells in a significant time and dose-dependent manner. DHA markedly strengthened the antiproliferative effect of 5-FU, decreasing the IC50 by 3.56-2.15-fold in an apparent synergy. The morphological changes of the cells were characterized by shrinkage, cell membrane blebbing and decreased adherence. Cell cycle analysis showed a shift of cells into the G0/G1 phase from the S phase following treatment with DHA or 5-FU(G0/G1 phase: 30.04% ± 1.54% vs 49.05% ± 6.41% and 63.39% ± 6.83%, respectively, P < 0.05; S phase: 56.76% ± 3.14% vs 34.75% ± 2.35% and 25.63% ± 2.21%, respectively, P < 0.05). Combination treatment of DHA and 5-FU resulted in a significantly larger shift toward the G0/G1 phase and subsequent reduction in S phase(G0/G1 phase: 69.06% ± 2.63% vs 49.05% ± 6.41% and 63.39% ± 6.83%, respectively, P < 0.05; S phase: 19.80% ± 4.30% vs 34.75% ± 2.35% and 25.63% ± 2.21%, respectively, P < 0.05). This synergy was also reflected in the significant downregulation of the expression of METCs in AGS cells.CONCLUSION: Synergistic anticancer properties of DHA and 5-FU may involve interference with energy production of AGS cells via downregulation of METCs and cell cycle arrest. | Kun Gao Qi Liang Zhi-Hao Zhao You-Fen Li Shu-Feng Wang | 2016 | World Journal of Gastroenterology2016，22，10： | 6 |
| 9 | 化疗对胃癌患者免疫功能的影响显示文摘背景:化疗药物可杀灭或抑制胃癌患者的肿瘤细胞,同时亦影响患者机体的免疫状态。分析胃癌患者化疗前后免疫状态的变化有助于准确实施化疗和综合治疗。目的:探讨化疗对胃癌患者免疫功能的影响。方法:共63例接受化疗的胃癌患者入选,化疗前后分别应用流式细胞仪和酶联免疫吸附测定(ELISA)检测外周血T细胞亚群和血清可溶性白细胞介素-2受体(sIL-2R)水平,并设健康者作为正常对照组。结果:胃癌患者化疗前CD3+、CD4+T细胞数以及CD4+/CD8+比值显著低于正常对照组(P<0.05),血清sIL-2R水平显著升高(P<0.05)。化疗后1周胃癌患者CD3+、CD4+T细胞数、CD4+/CD8+比值较化疗前显著降低(P<0.05),血清sIL-2R水平显著升高(P<0.05);化疗后3周,上述指标逐渐恢复,与化疗前水平相比无明显差异,但与正常对照组相比差异仍有统计学意义(P<0.05)。化疗过程中最常见的不良反应为恶心、呕吐(68.3%)和骨髓抑制(46.0%)。结论:胃癌患者在短期化疗后出现的免疫功能抑制需3周以上才能明显恢复。应于化疗早期使用免疫增强调节剂,以利于实施有效的综合治疗。 | 王吉 顾玮 孙颖 李健 胡梅洁 | 2008 | 胃肠病学2008，13，9： | 6 |
| 10 | 74例胃癌术后患者的预后因素分析显示文摘[目的]分析胃癌预后因素。[方法]对1998年~2005年我院收治的74例胃癌术后患者进行回顾性分析,采用LifeTable法、Kaplan-Meier和Cox回归分析对胃癌预后的影响进行评价。[结果]单因素分析显示临床分期、浸润深度、淋巴结转移、术后化疗和肿瘤残留情况与预后明显相关(P<0.05)。多因素分析显示术后化疗、肿瘤残留情况及临床分期为预后的独立因素(P<0.05)。[结论]术后化疗、肿瘤残留情况及临床分期是胃癌术后患者预后的独立危险因素。Ⅲ期胃癌术后患者接受辅助化疗具有明显的生存优势。 | 张煜 马力文 梁莉 | 2007 | 中国肿瘤2007，16，12： | 4 |
| 11 | 多西他赛联合奥沙利铂和氟尿嘧啶新辅助化疗治疗进展期胃癌的疗效显示文摘近年来国外多中心随机研究证实:新辅助化疗对延长胃食管肿瘤患者的生存期、降低病死率及提高R0切除率等方面疗效确切。本研究分析33例进展期胃癌患者应用多西他赛联合奥沙利铂及氟尿嘧啶方案进行新辅助化疗的疗效和毒副反应,现总结如下。 | 俞耀军 祁旦巳 孙维建 李丕宏 卢明东 王飞海 张毅 黄和 郑志强 | 2011 | 中华普通外科杂志2011，26，7： | 4 |
| 12 | Synergistic inhibitory effect of wogonin and low-dose paclitaxel on gastric cancer cells and tumor xenografts显示文摘Objective:To investigate the synergistic inhibitory effects of wogonin(WOG)and chemotherapeutic drugs on growth of gastric cancer cells and tumor xenografts.Methods:The IC50 values of WOG,cisplatin(CDDP)and paclitaxel(PTX)in four gastric cancer cell lines were determined by MTS assay.Hoechst staining and the median effect method of Chou-Talalay were used to assess the apoptosis of cells and the interaction of two drugs,respectively.BGC-823-derived xenografts in nude mice were established to investigate the effects of WOG combined with chemotherapeutic drugs in vivo.Results:WOG,CDDP and PTX inhibited the growth of BGC-823,MGC-803,MKN-45 and HGC-27 gastric cancer cells in a dose-dependent manner.WOG combined with CDDP or PTX synergistically inhibited the growth of all gastric cancer cell lines in vitro.In BGC-823,MGC-803,HGC-27 and MKN-45 cell lines,synergisms between WOG and PTX were shown when the fraction affected(Fa)values were<0.45,<0.90,<0.85 and<0.60.While WOG and CDDP had a synergistic inhibitory effect when the Fa values were>0,>0,>0.65 and>0.10.From the results of in vivo experiments using tumor xenografts,WOG and low-dose PTX showed better efficacy than either drug alone.The inhibitory percentages of tumor weight were 61.58%,20.29%,and 22.28%for the combination,WOG-alone,and low-dose PTX-alone groups,respectively.Notably,WOG combined with CDDP displayed very high toxicity.Conclusions:A synergistic inhibitory effect on growth was observed when WOG was combined with low-dose PTX in gastric cancer cells and tumor xenografts.These findings provide evidence for the design of a clinical trial to test the combination of WOG with low-dose PTX in human gastric cancer. | Tingting Wang Jing Gao Jingwei Yu Lin Shen | 2013 | Chinese Journal of Cancer Research2013，25，5： | 3 |
| 13 | 拉帕替尼治疗进展期胃癌的研究进展显示文摘胃癌是最常见的消化道恶性肿瘤之一,是世界癌症死亡第二位,中国是全球胃癌最高发区域,近一半的胃癌病例发生在中国,其发病率和死亡率在我国均高居癌症第二位。目前针对胃癌的治疗模式主要以手术、化疗和放疗的综合治疗为主,但进展期胃癌的预后仍然很差。随着肿瘤分子生物学的发展,肿瘤的治疗进入了分子靶向治疗时代。其中,上皮生长因子受体家族(HER/ErbB)在胃癌中存在广泛异常表达,并与胃癌的发生、发展及预后等密切相关。拉帕替尼作为EGFR/HER2双受体酪氨酸激酶抑制剂,在胃癌的各期临床试验中均显示了良好的结果。本文主要综述了拉帕替尼在胃癌治疗中的进展。 | 朱丹 张文 | 2013 | 大家健康(学术版)2013，，7： | 2 |
| 14 | 多西他赛联合奥沙利铂和5-氟尿嘧啶治疗进展期胃癌的监测与护理显示文摘胃癌是世界上死亡率位居第二的恶性肿瘤,我国处于胃癌高发区,其死亡率居恶性肿瘤之首。早期胃癌根治术后5年生存率在90%以上,但我国多数患者发现时即为进展期,单纯手术治疗效果不理想,总的5年生存率仅为20%~25%。近年来,国外多中心随机研究证实,应用多西他赛联合奥沙利铂及5-氟尿嘧啶(5-fluorouracil,5-Fu)进行新辅助化疗,对延长生存期、降低死亡率及提高R0级切除率等方面疗效确切。 | 吴朝晖 陈立浦 余慧茜 | 2011 | 中华危重症医学杂志(电子版)2011，4，1： | 2 |
| 15 | 胃癌肝转移的治愈性手术切除显示文摘1 临床资料患者男,55岁.主因进食后左季肋区胀痛10 d余,以“贲门癌”于2011年7月2日入院.患者于入院前10 d无有明显诱因出现进食后左季肋区胀痛不适感,无恶心、呕吐,无反酸,未解柏油样大便,体质量减轻5 kg,就诊于当地医院.当地医院胃镜检查结果:胃体上部癌(BorrmannⅡ型,侵犯贲门);病理学检查结果:胃体小弯处胃低分化腺癌.B超检查结果:肝脏肿大,肝内实质性占位性病变,肝癌多发;胆囊肿大,积液,胆囊炎.CT检查结果:胃体垂直部不均匀性增厚,考虑胃体癌,肝胃间隙内包块影,考虑肝内多发转移灶(图1). | 俞泽元 周辉年 郭凌云 罗长江 焦作义 | 2016 | 中华消化外科杂志2016，15，2： | 2 |
| 16 | Her-2与胃癌的分子靶向治疗显示文摘人表皮生长因子受体-2(Her-2)是一种具有酪氨酸激酶活性的185000的跨膜糖蛋白,在细胞分裂增殖信号跨膜转导中发挥重要功能,最终从多个途径影响肿瘤细胞的生物活动,如肿瘤细胞增殖、黏附、转移和分化等相关基因的调控。研究表明Her-2在胃癌患者中过表达率约12%~35%,是胃癌的预后不良因素,而Her-2单克隆抗体曲妥珠单抗有望成为Her-2过表达胃癌患者的新的标准治疗。 | 李明新 于忠和 | 2011 | 国际肿瘤学杂志2011，38，9： | 1 |
| 17 | 替吉奥联合多西他赛方案治疗进展期胃癌的临床观察显示文摘目的观察替吉奥联合多西他赛治疗进展期胃癌的近期疗效和毒副反应。方法 44例进展期胃癌患者采用以下方法化疗:替吉奥胶囊每天80 mg/m^2,分2次,餐后口服,第1~14天;多西他赛75 mg/m^2,第1天,静脉滴注2~3 h,21d为1个周期,至少完成2个周期。评价客观疗效和不良反应。结果 44例均可以评价疗效。CR 3例(6.8%),PR 18例(40.9%),SD 14例(31.8%),PD 9例(20.5%),RR 47.7%,DCR 79.5%。中位疾病进展时间为7.2月,中位生存期为11.3月。不良反应主要是骨髓抑制、胃肠道反应、脱发及口腔黏膜炎。结论替吉奥联合多西他赛方案治疗进展期胃癌的疗效较好,不良反应可以耐受,值得进一步研究应用。 | 韩守恒 戴文香 伍尤华 | 2012 | 湘南学院学报(医学版)2012，14，2： | 1 |
| 18 | DOF和DCF方案治疗进展期胃癌的疗效分析显示文摘目的分析比较多西他赛联合奥沙利铂、氟尿嘧啶(DOF方案)与联合顺铂、氟尿嘧啶(DCF方案)治疗进展期胃癌(Advanced gastric cancer)患者的初步疗效和患者的耐受性。方法 75例晚期胃癌患者,分别接受DOF方案或DCF方案治疗,DOF组37例,DCF组38例。两组患者特征具有可比性(P﹥0.05)。结果两组均有35例可以评价疗效。DOF组有效率为45.71%(16/35),其中CR 2例;DCF组有效率为42.86%(15/35),其中CR 1例。DOF组中位无进展时间为5.6月,DCF组中位无进展时间为5.8月。DOF组中位生存期9.5月;DCF组中位生存期9.7月。两组毒性反应主要为骨髓抑制,胃肠道反应,肾毒性和神经毒性。结论 DOF方案和DCF方案治疗进展期胃癌疗效相似,但DOF方案比DCF方案的耐受性要好。 | 韩守恒 戴文香 伍尤华 | 2012 | 中南医学科学杂志2012，40，6： | 1 |
| 19 | Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma显示文摘AIM: To examine the extent of use of specific therapies in clinical practice, and their relationship to therapies validated in clinical trials. METHODS: The US National Cancer Institutes’ Patterns of Care study was used to examine therapies and survival of patients diagnosed in 2001 with histologically-confirmed gastroesophageal adenocarcinoma (n = 1356). The study re-abstracted data and verified therapy with treating physicians for a population-based stratified random sample. RESULTS: Approximately 62% of patients had stomach adenocarcinoma (SAC), while 22% had gastric-cardia adenocarcinoma (GCA), and 16% lower esophageal adenocarcinoma (EAC). Stage Ⅳ/ unstaged esophageal cancer patients were most likely and stage Ⅰ-Ⅲ stomach cancer patients least likely to receive chemotherapy as all or part of their therapy; gastric-cardia patients received chemotherapy at arate between these two. In multivariable analysis by anatomic site, patients 70 years and older were significantly less likely than younger patients to receive chemotherapy alone or chemoradiation for all three anatomic sites. Among esophageal and stomach cancer patients, receipt of chemotherapy was associated with lower mortality; but no association was found among gastric-cardia patients. CONCLUSION: This study highlights the relatively low use of clinical trials-validated anti-cancer therapies in community practice. Use of chemotherapy-based treatment was associated with lower mortality, dependent on anatomic site. Findings suggest that physicians treat lower esophageal and SAC as two distinct entities, while gastric-cardia patients receive a mix of the treatment strategies employed for the two other sites. | Deirdre P Cronin-Fenton Margaret M Mooney Limin X Clegg Linda C Harlan | 2008 | World Journal of Gastroenterology2008，14，20： | 0 |
| 20 | 同时性胃癌肝转移行同期胃癌联合肝转移灶切除术的可行性显示文摘胃肠道恶性肿瘤肝转移是一种临床上常见、处理较棘手的情况。其中,结直肠癌肝转移患者可以从肝脏转移灶切除术中获益,并且随着手术技术和围术期处理水平的不断提高,肝脏切除术的适应症不断拓宽。但在胃癌肝转移的患者中,因为肝转移灶通常为多发、散在、左右两叶转移,仅有少数患者适宜行肝脏切除术,目前仅有少数有关胃癌肝转移行同期手术切除的报道,且手术疗效参差不齐。因此,有关同时性胃癌肝转移行同期胃癌联合肝转移灶切除术的适应症和疗效仍存在争议。本文综合文献分析,结合自身科室收治的同时性胃癌肝转移行同期手术切除的病例随访资料,对其手术指征和预后影响因素进行探讨。 | 杨新伟 刘凯 栗玉龙 常颜信 段纪成 刘虎 杨家和 吴孟超 | 2019 | 肝胆外科杂志2019，27，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员